
    
      *Study Objective: After repeated administration of BR9003 2mg and BR9003A 1mg for healthy
      adult volunteers, the pharmacokinetic properties and safety are evaluated.

        -  Target number of subjects for enrollment (randomization):

           24 subjects in total (2 sequence groups(A or B), 12 subjects per sequence group)

        -  Investigational Product

             1. Control drug: BR9003A 1mg

             2. Test drug: BR9003 2mg

        -  Regimen

             1. Control group: Administration of BR9003A 1mg twice a day for six days

             2. Test group: Administration of BR9003 2mg once a day for six days
    
  